Cyclin D1 and p16 expression in recurrent nasopharyngeal carcinoma
© Lin et al. 2006
Received: 30 January 2006
Accepted: 05 September 2006
Published: 05 September 2006
Cyclin D1 and p16 are involved in the regulation of G1 checkpoint and may play an important role in the tumorigenesis of nasopharyngeal carcinoma (NPC). Previous studies have examined the level of expression of cyclin D1 and p16 in primary untreated NPC but no such information is available for recurrent NPC. We set out in this study to examine the expression level of cyclin D1 and p16 in recurrent NPC that have failed previous treatment with radiation +/- chemotherapy.
Patients and methods
A total of 42 patients underwent salvage nasopharyngectomy from 1984 to 2001 for recurrent NPC after treatment failure with radiation +/- chemotherapy. Twenty-seven pathologic specimens were available for immunohistochemical study using antibodies against cyclin D1 and p16.
Positive expression of cyclin D1 was observed in 7 of 27 recurrent NPC specimens (26%) while positive p16 expression was seen in only 1 of 27 recurrent NPC (4%).
While the level of expression of cyclin D1 in recurrent NPC was similar to that of previously untreated head and neck cancer, the level of p16 expression in recurrent NPC samples was much lower than that reported for previously untreated cancer. The finding that almost all (96%) of the recurrent NPC lack expression of p16 suggested that loss of p16 may confer a survival advantage by making cancer cells more resistant to conventional treatment with radiation +/- chemotherapy. Further research is warranted to investigate the clinical use of p16 both as a prognostic marker and as a potential therapeutic target.
Nasopharyngeal carcinoma (NPC) is a prevalent malignancy in Southeast Asia with reported incidence rate ranging from 10 to 53 cases per 100,000 persons per year . Although it is a relatively uncommon cancer in western countries with an incidence rate of less than 1 case per 100,000, it poses a significant health problem in regions of the US where there is large population of Asians. External beam radiation therapy is considered the primary mode of treatment for previously untreated NPC. This is mainly due to the high degree of sensitivity of this tumor to radiation as well as the anatomic constraints for surgical access in this highly complex region. Despite advances in diagnostic and treatment modalities, loco-regional failure is still significant with reported rates of 15.6% to 58% [1, 2]. The addition of chemotherapy concurrent with radiation has been shown to improve survival in patients with NPC .
Although the molecular events responsible for the pathogenesis of NPC remain to be elucidated, the final common pathway appears to be a disruption of the mechanisms involved in the regulation of cell cycle progression, leading to uncontrolled cell proliferation. The most critical point in cell cycle regulation is the G1 checkpoint. It is here that complex interactions take place to determine whether the cell will exit the cell cycle and go into a quiescent state (G0) or enter into the S phase and proceed with cell division . These complex interactions involve a large number of regulatory proteins such as cyclins, cyclin-dependent kinases (CDKs), and CDK-inhibitors. Among the cyclins involved in G1 phase, cyclin D1 appears to be most strongly implicated in human carcinogenesis. Cyclin D1, through its interaction with cyclin-dependent kinase-4 or 6 (CDK-4/6), forms a complex that inactivates the tumor suppressor protein retinoblastoma (pRb) through phosphorylation . Phosphorylation of pRb releases transcription factors such as E2Fs which then activate a series of events that allow entry into S-phase and cell division . An increased level of cyclin D1 expression has been reported in a number of malignancies  including esophageal, ovarian, breast, uterine, colon, lung, prostate, lymphoma, as well as head and neck cancers. Between 30% to 83% of head and neck squamous cell carcinoma (HNSCC) were reported to be associated with cyclin D1 over-expression [6, 7]. The progression of cells from G1 to S phase, on the other hand, is blocked by a potent tumor suppressor protein, p16, which acts to disrupt the cyclin D1/CDK-4/6 complex. Deletions, mutations, or methylation of the p16 gene has been implicated in the development of a variety of human malignancies, including head and neck cancer [6, 8].
The disruption of the "Retinoblastoma/cyclin D1/p16 pathway" involved in the regulation of the G1 checkpoint also appears to play an important role in the tumorigenesis of NPC. Over-expression of cyclin D1 and/or loss of p16 has been reported in several studies on NPC. These studies found an increased level of cyclin D1 expression in 30%  to 66%  and the lack of expression of p16 in 40% to 70% of previously untreated NPC specimens [9–12].
Although a large body of data exists on cyclin D1 and p16 expressions in HNSCC including NPC, to the best our knowledge, no previous studies have been reported on the expression level of these proteins in recurrent HNSCC. We set out in this study to examine the expression level of cyclin D1 and p16 in recurrent NPC that have failed previous treatment with radiation +/- chemotherapy.
A total of 42 patients underwent salvage nasopharyngectomy by one of the investigators (WEF) at Stanford University Medical Center from 1984 to 2001 for recurrent NPC after treatment failure with radiation +/- chemotherapy. The clinical, demographic, and results of salvage nasopharyngectomy on the first 37 patients have been published previously . Between 2000 and 2001, 5 additional patients underwent nasopharyngectomy, bringing the total number of patients to 42. A search through the archival tissue bank at Stanford Medical Center identified 27 pathologic specimens which were available for immunohistochemical study using antibodies against cyclin D1 and p16. The other 15 specimens were unavailable for this study due to exhaustion of the limited amount of pathological specimen during the original pathologic diagnosis.
The surgical approach for the salvage nasopharyngectomy depended on the location of the tumor but included intraoral, transpalatal, and sublabial transmaxillary approaches. Isolation of the internal carotid artery and cranial nerves IX, X, and XII to the skull base was performed. Tumors were removed en bloc when possible. Any recurrent neck disease was addressed with a neck dissection. There was no evidence of distant metastasis in any of these study patients. At the time of salvage surgery, 20 patients have previously been treated with 1 course of radiation, 2 patients with 2 courses of radiation, 2 patients with 2 courses of radiation plus chemotherapy, and 3 patients with a single course of radiation plus chemotherapy.
Immunohistochemistry for cyclin D1 and p16
Using the Biogenex i1000, deparaffinization and microwave antigen retrieval were performed on the tissue sections. This was followed by immunostaining using the Dako Autostainer. Briefly, the slides were incubated in 0.3% hydrogen peroxide and blocked using a non-serum based blocking agent. The slides were then incubated with primary monoclonal mouse anti-cyclin D1 antibody (dilution 1:25; Zymed, South San Francisco, CA) and monoclonal anti-p16 antibody (F-12) (dilution 1:40; Santa Cruz Biotechnology, Santa Cruz, CA) for 60 minutes at room temperature. Following the primary incubation, the slides were incubated with biotinylated goat anti-mouse antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 10 minutes followed by incubation with strepavidin-peroxidase reagent for 10 minutes. Finally, the slides were visualized using DAB and counterstained with Mayer's hematoxylin.
Analysis of level of expression
Immunostaining of cyclin D1 and p16 was evaluated by a board-certified pathologist (GJB). Ten high power fields were successively examined using standard light microscopy. Cytoplasmic reactivity was disregarded as nonspecific and only staining of tumor nuclei was scored as positive. A specimen was scored as negative or no staining (0) when < 5% of the tumor cells exhibited nuclear staining. A specimen was considered positive when > 5% of the tumor cells exhibited nuclear staining. The 5% cut-off for positivity was chosen in order to be consistent with other similar studies on p16 and cyclin D immunostaining in the literature. Non-uniform staining of p16 and cyclin D1 was expected since the expression of these 2 proteins in a particular tumor cell is dependent on the phase of cell cycle with a peak expression in G1 phase. The intensity of the positive immunostains were then graded semi-quantitatively as 1+ (positive/weak staining), 2+ (positive/moderate staining), and 3+ (positive/strong staining) (additional file 1).
Overall disease-free survival was calculated using the Kaplan-Meier program from SPSS 14.0 for Windows (SPSS, Chicago, IL). Significance in survival outcome between different groups of patients in this study population was analyzed by the Log-rank test (Mantel-Cox).
Twenty-seven recurrent NPC specimens were examined in this study. The average age at the time of salvage nasopharyngectomy was 51 years (range, 27 to 72 years). There were 18 men and 9 women. Thirteen patients were Asian and 14 were non-Asians. Patients were restaged using the 1998 AJC Cancer Staging Manual and 16 were staged as recurrent (r)T1, 2 as rT2, 5 as rT3, and 4 as rT4. Other relevant clinicopathological characteristics of these patients were shown in additional file 1.
The results of the immunohistochemical staining of these 27 recurrent NPC specimens were presented on additional file 1. Cyclin D1 over-expression was limited to tumor cells and no immunostaining was noted on the surrounding normal epithelium of the nasopharynx. Thus, the normal epithelium served as internal negative control. On the other hand, normal tissue stained positive for p16 and was used as internal positive control. Representative samples of cyclin D1 and p16 immunostaining were shown in Figure 1. Absence of staining for cyclin D1 and p16 were illustrated in panel C and D respectively. In Panel E and F, 3+ immunostaining was demonstrated for cyclin D1 and p16 respectively. Of the 27 recurrent NPC specimens, 7 (26%) stained positive for cyclin D1 proteins while only 1 (4%) demonstrated immunostaining for p16. Of the 7 specimens that stained positive for cyclin D1 protein, 1 stained strongly (3+), 3 stained moderately (2+), and 3 stained weakly (1+).
In this study, we examined the expression level of cyclin D1 and p16 in recurrent NPC that have failed previous treatment with radiation +/- chemotherapy. These specimens were procured at the time of salvage nasopharyngectomy. We found over-expression of cyclin D1 in 26% and the lack of expression of p16 in 96% of recurrent NPC specimens. While the level of over-expression of cyclin D1 (26%) in recurrent NPC specimens was similar to the levels of over-expression (30% to 66%) found in primary untreated NPC, the lack of expression of p16 in recurrent NPC specimens (96%) was significantly higher than those typically reported for primary untreated NPC (40% to 70%) [9–12].
There are a number of studies that attempted to correlate the level of expression of cyclin D1 and p16 in cancer with prognosis. Several investigators reported association between over-expression of the proto-oncogene cyclin D1 with worse prognosis in terms of shorter survival and increased incidence of recurrence [14–16]. This poor prognosis in tumors over-expressing cyclin D1 was found to be independent of other clinicopathological parameters such as tumor stage, nodal or distant metastasis, or degree of differentiation [14–16]. Other studies however either failed to show this association between over-expression of cyclin D1 and poor clinical outcome  or found a reverse association between over-expression of cyclin D1 and poor prognosis. In a series of 65 patients, Hwang et al  reported that loss of cyclin D1 was closely related to local recurrence after radiation therapy for NPC. Our data also failed to support the association between over-expression of cyclin D1 with increased risk of recurrence. If over-expression of cyclin D1 was associated with increased risk of recurrence, we would expect to find a higher proportion of recurrent NPC specimens to over-express cyclin D1 compared to previously untreated NPC. However, the level of over-expression of cyclin D1 in recurrent NPC specimens found in this study (26%) was not higher, but slightly lower than those reported for previously untreated NPC (30% to 66%) [7, 9, 18].
Four different studies showing that between 40% to 70% of previously untreated NPC specimens have loss of p16 expression.
Finally, it is interesting to note that Asian patients, following treatment with salvage nasopharyngectomy, have a statistically significant better 5-year disease-free survival compared to Caucasians and Hispanics (p = 0.003) (Figure 5). The reason for this difference is unclear. The Asian and non-Asian group did not differ significantly in their level of cyclin D1 expression. Four out of 13 Asians and 3 out of 14 non-Asians stained positive for cyclin D1.
Although this is the first study looking at the expression levels of cyclin D1 and p16 in recurrent NPC, this study has several limitations. First, pre-irradiated NPC specimen were not available for use as control due to the fact that most of these patients were referred from outside institutions (in many cases, from institutions outside of US) after treatment failure with radiation therapy. The unavailability of pre-irradiated NPC specimen raised the issue of whether the lack of expression of p16 in these recurrent NPC samples was pre-existing (pre-treatment) or the result of selection pressure from treatment. The data presented in this study will not be able to answer this question. Our assumption here was that these recurrent tumors would have the same staining characteristics showing absence of p16 expression even before treatment with radiation. Irrespective of whether the p16 expression was lost during tumor transformation (before treatment) or during treatment with radiation, this marked reduction of p16 in recurrent NPC specimen underscored the importance of p16 alteration in NPC and provided support for therapeutic strategies that aim to restore p16 expression. There have been pre-clinical studies which demonstrated the ability of exogenously introduced p16 to inhibit proliferation and induce apoptosis in NPC cell culture . Another limitation of this study was the small number of cases (n = 27) examined. However, both the low prevalence of NPC in the US and the reluctance of most head and neck surgeons to surgically salvage recurrent NPC made access to a large number of surgically removed recurrent NPC specimen available for immunohistochemical study difficult.
In this study, we have determined the level of expression of cyclin D1 and p16 in recurrent NPC that have failed primary treatment with radiation +/- chemotherapy. While the level of expression of cyclin D1 in recurrent NPC was similar to that of previously untreated HNSCC, almost all of the recurrent NPC samples lacked expression of p16 protein. This finding suggested that the loss of p16 tumor suppressor protein in NPC may be associated with higher rate of failure after treatment with radiation +/- chemotherapy. Thus, p16 expression level appeared to be a clinically useful prognostic marker in NPC and warranted further investigations. Further, therapeutic strategies targeting the p16 pathway may be a promising approach to improve the treatment outcome of NPC. Several promising studies have demonstrated the ability of exogenously introduced p16 to inhibit proliferation and induce apoptosis in NPC cell culture .
This study is supported by a grant from Patricia L. Knebel Memorial Fund from The Pittsburgh Foundation, Pittsburgh, PA. HSL is supported by the VA MREP grant from John D. Dingell VA Medical Center and Binn's fund from the Department of Otolaryngology-Head and Neck Surgery at Wayne State University.
- Bailet JW, Mark RJ, Abemayor E, Lee SP, Tran LM, Juillard G, Ward PH: Nasopharyngeal carcinoma: treatment results with primary radiation therapy. Laryngoscope 1992, 102:965–972.PubMed
- Lee AW, Law SC, Ng SH, Chan DK, Poon YF, Foo W, Tung SY, Cheung FK, Ho JH: Retrospective analysis of nasopharyngeal carcinoma treated during 1976–1985: late complications following megavoltage irradiation. Br J Radiol 1992, 65:918–928.View ArticlePubMed
- Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16:1310–1317.PubMed
- Sherr CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000, 60:3689–3695.PubMed
- Bartkova J, Lukas J, Strauss M, Bartek J: Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995, 10:775–778.PubMed
- Lai S, El-Naggar AK: Differential expression of key cell cycle genes (p16/cyclin D1/pRb) in head and neck squamous carcinomas. Lab Invest 1999, 79:255–260.PubMed
- Namazie A, Alavi S, Olopade OI, Pauletti G, Aghamohammadi N, Aghamohammadi M, Gornbein JA, Calcaterra TC, Slamon DJ, Wang MB, Srivatsan ES: Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 2002, 112:472–481.View ArticlePubMed
- Olshan AF, Weissler MC, Pei H, Conway K, Anderson S, Fried DB, Yarbrough WG: Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene 1997, 14:811–818.View ArticlePubMed
- Hwang CF, Cho CL, Huang CC, Wang JS, Shih YL, Su CY, Chang HW: Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol 2002, 13:1246–1251.View ArticlePubMed
- Baba Y, Tsukuda M, Mochimatsu I, Furukawa S, Kagata H, Satake K, Koshika S, Nakatani Y, Hara M, Kato Y, Nagashima Y: Reduced expression of p16 and p27 proteins in nasopharyngeal carcinoma. Cancer Detect Prev 2001, 25:414–419.PubMed
- Huang GW, Mo WN, Kuang GQ, Nong HT, Wei MY, Sunagawa M, Kosugi T: Expression of p16, nm23-H1, E-cadherin, and CD44 gene products and their significance in nasopharyngeal carcinoma. Laryngoscope 2001, 111:1465–1471.View ArticlePubMed
- Makitie AA, MacMillan C, Ho J, Shi W, Lee A, O'sullivan B, Payne D, Pintilie M, Cummings B, Waldron J, Warde P, Irish J, Brown D, Gilbert R, Gullane P, Liu FF, Kamel-Reid S: Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 2003, 9:2177–2184.PubMed
- Fee WE Jr, Moir MS, Choi EC, Goffinet D: Nasopharyngectomy for recurrent nasopharyngeal cancer: a 2- to 17-year follow-up. Arch Otolaryngol Head Neck Surg 2002, 128:280–284.PubMed
- Kuo MY, Lin CY, Hahn LJ, Cheng SJ, Chiang CP: Expression of cyclin D1 is correlated with poor prognosis in patients with areca quid chewing-related oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 1999, 28:165–169.View ArticlePubMed
- Mathew R, Arora S, Khanna R, Shukla NK, Mathur M, Ralhan R: Alterations in cyclin D1 expression in esophageal squamous cell carcinoma in the Indian population. J Cancer Res Clin Oncol 2001, 127:251–257.View ArticlePubMed
- Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995, 55:975–978.PubMed
- Vielba R, Bilbao J, Ispizua A, Zabalza I, Alfaro J, Rezola R, Moreno E, Elorriaga J, Alonso I, Baroja A, de la Hoz C: p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope 2003, 113:167–172.View ArticlePubMed
- Lai JP, Tong CL, Hong C, Xiao JY, Tao ZD, Zhang Z, Tong WM, Betz CS: Association between high initial tissue levels of cyclin d1 and recurrence of nasopharyngeal carcinoma. Laryngoscope 2002, 112:402–408.View ArticlePubMed
- Wang GL, Lo KW, Tsang KS, Chung NY, Tsang YS, Cheung ST, Lee JC, Huang DP: Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. Br J Cancer 1999, 81:1122–1126.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.